Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Synergy Pharmaceuticals, Inc.
420 Lexington Avenue
Suite 2012
New York, NY 10170
United States
212-297-0020
http://www.synergypharma.com
ynergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333, which is in Phase II clinical trials to treat opioid induced constipation, as well as in Phase Ib clinical trials to treat ulcerative colitis. The company has a research collaboration with BIND Therapeutics, Inc. to develop ACCURINS for treatment of a range of cells with novel therapeutic payloads. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.